Impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes and long-term survival following percutaneous coronary rotational atherectomy

Journal of Thrombosis and Thrombolysis

Volumn 19, Issue 1, 2005, Pages 47-54

  Berger, Jeffrey S ^a   Slater, James N ^b   Sherman, Warren ^c   Green, Stephen J ^d   Sanborn, Timothy A ^e   Brown, David L ^f  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^e EVANSTON HOSPITAL   (United States)

^f STONY BROOK UNIVERSITY   (United States)

Author keywords

Atherectomy; Platelet aggregation inhibitors

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN; ORAL ANTIDIABETIC AGENT; TIROFIBAN;

AGED; ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DATA ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HOSPITAL PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONBIOLOGICAL MODEL; OUTCOMES RESEARCH; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; ROTATIONAL ATHERECTOMY; STATISTICAL ANALYSIS; SURVIVAL TIME; UNSTABLE ANGINA PECTORIS;

ATHERECTOMY, CORONARY; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY FAILURE; MALE; MIDDLE AGED; NEW YORK; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREVALENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS;

EID: 21844464602     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-005-0355-4     Document Type: Article

References (33)

1. Khoury A, Kern MJ. Coronary physiology of percutaneous rotational atherectomy. Cath Cardiovasc Diag Supplement 1996;3:15-22.
2. Safian RD, Niazi KA, Strzelecki M, et al. Detailed angiographic analysis of high-speed mechanical rotational atherectomy in human coronary arteries. Circulation 1993;88:961-968. 1:STN:280:ByyA2MfksFE%3D
3. Teirstein PS, Warth DC, Haq N, et al. High speed rotational coronary atherectomy for patients with diffuse coronary artery disease. J Am Coll Cardiol 1991;18:1964-1671.
4. Warth DC, Leon MB, O'neill W, Zacca N, Polissar NL, Buchbinder M. Rotational atherectomy multicenter registry: Acute results, complications and 6-month angiographic follow-up in 709 Patients. J Am Coll Cardiol 1994;24:641-648. 1:STN:280:ByuA2MfislI%3D
5. Bertrand ME, Lablanche JM, Leroy F, et al. Percutaneous transluminal coronary rotary ablation with Rotablator (European experience). Am J Cardiol 1992;69:470-474. 10.1016/0002-9149(92)90988-B
6. Koch K, Kleinhans E, Klues HG, et al. Quantitative assessment of transient regional ischemia during rotational atherectomy. J Nucl Med 1998;39:402-408 1:STN:280:DyaK1c7ovVWgsw%3D%3D
7. Williams MS, Coller BS, Vaananen HJ, Scudder LE, Sharma SK, Marmur JD. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abcimixab (c7E3 Fab; ReoPro). Circulation 1998;98:742-748. 1:CAS:528:DyaK1cXlvVyjur4%3D
8. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
9. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
10. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435.
11. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
12. Brener SJ, Barr LA, Burchenal JEB, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734-741. 1:CAS:528:DyaK1cXlvVyjtbc%3D
13. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-1428.
14. The ESPRIT Investigators. Novel dosing regimen in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 2000;356:2037-2044.
15. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-1453.
16. Boyle CA, Decoufle P. National sources of vital status information: extent of coverage and possible selectivity in reporting. Am J Epidemiol 1990;131:160-168. 1:STN:280:By%2BD1cnnsFY%3D
17. Newman TB, Brown AN. Use of commercial record linkage software and vital statistics to identify patient deaths. J Am Med Inform Assoc 1997;4:233-237. 1:STN:280:ByiB1M3osVU%3D
18. Kini A, Reich, D, Marmur JD, Mitre CA, Sharma SK. Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions: Results of the Rota Reopro randomized trial. Am Heart J 2001;142:965-969. 10.1067/mhj.2001.119382
19. Steinbuhl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-assessing Ultegra) multicenter study. Circulation 2001;103:2572-2578. 1:CAS:528:DC%2BD3MXltVansLw%3D
20. Byrne A, Moran N, Maher M, Walsh N, Crean P, Fitzgerald DJ. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty. Arterioscler Thromb Vasc Biol 1997;17:3224-3229. 1:CAS:528:DyaK1cXisV2msw%3D%3D
21. Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc Res. 2000;45:437-446. 10.1016/S0008-6363(99)00253-9
22. Klinkhardt U, Kirchmaier CM, Westrup D, et al. Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abciximab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters. Thromb Res. 2000;97:201-207. 10.1016/ S0049-3848(99)00155-3
23. Cierniewski CS, Byzova T, Papierak M, et al. Peptide ligands can bind to distinct sites in integrin αIIbβ3 and elicit different functional responses. J Biol Chem. 1999;274:16923-16932. 10.1074/jbc.274.24.16923
24. Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors. Blood 1998;92:3240-3249. 1:CAS:528:DyaK1cXntFCqsbk%3D
25. Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy. Am J Cardiol 2000;85:491-493. 10.1016/ S0002-9149(99)00778-X
26. Koch K, vom Dahl J, Kleinhans E, et al. Influence of a platelet GPIIb/ IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. J Am Coll Cardiol 1999;33:998-1004. 10.1016/S0735-1097(98)00659-7
27. Ellis SG, Popama JJ, Buchbinder M, et al. Relation of clinical presentation, stenosis morphology, and operator technique to the procedural results of rotational atherectomy and rotational atherectomy-facilitated angioplasty. Circulation 1994;89:882-892. 1:STN:280:ByuC2cjmt1A%3D
28. Kini A, Marmur JD, Duvvuri S, Dangas G, Choudhary S, Sharma SK. Rotational Atherectomy: Improved procedural outcome with evolution of technique and equipment. Single center results of first 1,000 patients. Cath Cardiovasc Intervent 1999;46:305-311. 10.1002/ (SICI)1522-726X(199903)46:3<305::AID-CCD9>3.0.CO;2-U
29. Anderson KA, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001;37:2059-2065. 10.1016/ S0735-1097(01)01290-6
30. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2002;104:163-167.
31. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? (editorial). N Engl J Med 2000;342:1907-1909. 10.1056/NEJM200006223422511
32. Concato J, Shah N, Horowitz RI. Randomized controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-1892. 10.1056/NEJM200006223422507
33. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-1886. 10.1056/ NEJM200006223422506